Advertisement

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Anas Younes, Yasuhiro Oki, Peter McLaughlin, Amanda R. Copeland, Andre Goy, Barbara Pro, Lei Feng, Ying Yuan, Hubert H. Chuang, Homer A. Macapinlac, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Michelle A. Fanale, Bouthaina Shbib Dabaja, Maria A. Rodriguez, Nam Dang, Larry W. Kwak, Sattva S. Neelapu and Luis E. Fayad

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

No eLetters have been published for this article.